Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$3.87 USD
-0.16 (-3.97%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 21 - 40 ( 155 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Fiscal 1Q Results: $155M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX3-71 Study Publication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Dual Mechanisms in Alzheimer''s Bode Well for Blarcamesine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Potential Disease-Modifying Impact in Rett Syndrome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: 2-73 Shows a Disease Modifying Effect in Rett?s Patients
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Additional IP to 2036 Helps Secure Valuation
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Completion of ANAVEX?2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Rett Syndrome Data Release Approaching; F2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Reports the Quarter - $153M in Cash and Equivalents - Looking at Accelerated Pathway for Alzheimer?s
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
New Blarcamesine Patent Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Long-Term Parkinson''s Disease Benefit; Raising PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex 2-73 Shows Long-Term Benefit in Parkinson?s Disease Dementia Going Pivotal Now
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Hires Ex-FDA Biostatistician CNS Expert
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Reports Fiscal 1st QTR: $15M Burn, $143M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Rett Phase 2/3 Trial Enrollment Target Exceeded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Rett Syndrome Trial Exceeds Enrollment
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Promise in Alzheimer''s Disease; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: ANAVEX2-73 Study Meets Its Primary and Key Secondary Endpoints
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J